Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic...

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Immune checkpoint inhibitors (ICIs) targeting programed cell death 1 (PD-1) or PD-L1 are key immunotherapies for cancers like non-small cell lung cancer (NSCLC).
• Recent clinical trials combining ICIs with chemotherapy have established new first-line treatments for advanced NSCLC.
• Current predictive markers like PD-L1 scores and tumor mutational burden are insufficient for determining ICI efficacy.

Purpose of the Study:

• To review recent clinical trials of ICIs in advanced NSCLC.
• To explore the association between driver alterations in NSCLC and distinct immune phenotypes.
• To discuss current clinical challenges and future directions for precision medicine in NSCLC.

Main Methods:

• Review of pivotal clinical trials involving ICIs in advanced NSCLC.
• Analysis of molecular biological approaches, including multi-omics, to understand cancer immune escape.
• Examination of the relationship between driver mutations and immune phenotypes in NSCLC.

Main Results:

• Specific driver mutations in NSCLC are associated with distinct immune phenotypes.
• Driver mutations influence the regulatory mechanisms of PD-L1 expression.
• Multi-omics analyses are revealing new mechanisms of cancer immune escape.

Conclusions:

• Understanding the interplay between driver mutations and immune phenotypes is crucial for optimizing ICI therapy in NSCLC.
• Precision medicine approaches are essential for tailoring NSCLC treatment based on molecular profiles.
• Further research is needed to overcome current clinical limitations and improve patient outcomes.